# GHK-Cu: What Would Need to Change for Availability **By TelosRX Editorial Team** ยท 2026-09-21 **GHK-Cu is a small copper-binding peptide studied for skin and tissue repair, and telos rx does not currently offer it as part of its compounding program. This article explains what the peptide is, why it is not available yet, and what would actually need to happen before that changes.** What to know GHK-Cu is not currently offered by telos rx for compounding. It is under review, not approved, and there is no confirmed date for when or whether that will change. If you want to start a compounded peptide protocol today, telos rx currently offers BPC-157, PT-141, NAD+ nasal spray, and sermorelin. ## What GHK-Cu is GHK-Cu, sometimes written as copper peptide or copper tripeptide-1, is a naturally occurring combination of three amino acids bound to a copper ion. It is present in human blood plasma and other tissues, and levels of it are known to decline with age. Researchers have studied it for decades as part of the body's own wound-healing and tissue-remodeling processes. Most of the public interest in GHK-Cu comes from its use in topical skincare, where it appears as an ingredient in serums and creams marketed for firmness and collagen support. Separately, [published research on the peptide](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/) has also studied injectable or compounded forms in the context of tissue repair. Those are different delivery routes with different evidence bases, and it is worth being precise about which one a source is actually discussing. Compounded medications, as a category, are not FDA-approved. A compounded version of a peptide like GHK-Cu is prepared by a licensed pharmacy for an individual patient rather than manufactured and approved the way a mass-market prescription drug is. That is true of every compounded peptide, whether or not a specific pharmacy currently offers it. ## Where GHK-Cu stands with telos rx today telos rx does not currently offer GHK-Cu for compounding. It is not part of the active treatment program, it cannot be added to an existing plan, and there is no intake for it. If a website or a social post implies otherwise about telos rx, that information is outdated or wrong. This is a program decision, not a claim that the peptide has been rejected outright. telos rx is reviewing GHK-Cu alongside several other research peptides for possible future inclusion in its compounding program. Reviewing is an ongoing internal process. It does not carry a timeline, and no particular outcome is assured. You can read more about telos rx's current status on [GHK-Cu](https://www.telosrx.com/pages/ghk-cu). It helps to separate three different things that are easy to blur together. A peptide can exist in research literature, receive a nonbinding regulatory recommendation, or actually be offered by a specific telehealth program. GHK-Cu sits in the first two categories for telos rx, but not the third. **Key takeaway:** GHK-Cu is under review at telos rx, not offered today, and not on any confirmed timeline. Anything implying otherwise is not accurate. ## What would actually need to change for it to become available A few distinct things would need to line up before telos rx could reasonably add GHK-Cu to its compounding program. None of them are certain to happen, and none of them have a set date attached. The first is regulatory clarity at the federal level. In 2026, a federal advisory body called the Pharmacy Compounding Advisory Committee, or PCAC, made nonbinding recommendations touching on a number of research peptides. A recommendation from an advisory committee is input for regulators to consider, not a rule that takes effect on its own. Formal rulemaking, if it happens, moves on its own schedule and can differ from what an advisory committee recommended. The second is telos rx's own internal review of the compounding, sourcing, and quality evidence for the peptide, done with its partner pharmacies. Even once a substance is legally compoundable, a telehealth program still has to decide it belongs in its own catalog. That decision involves its own clinical and operational review, separate from the federal question. The third is a genuine clinical case for offering it responsibly. That means enough of an evidence base and a defined patient population for a licensed provider to make sound, individualized decisions rather than approving requests on demand. Until those three things converge, GHK-Cu stays outside the program, however promising early research on it may be. ## The 2026 PCAC review and why it is not approval It is worth being specific about what actually happened in 2026, because the distinction gets flattened in a lot of casual coverage. The PCAC reviewed several research peptides, including some that overlap with substances people search for by name. It issued recommendations about how they might eventually be handled under compounding rules. A recommendation is advice given to a regulator. It is not a new law, a new approval, and not a change to what [pharmacies are currently permitted to compound](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) under federal rules. Nothing about the PCAC process made GHK-Cu newly available anywhere, at telos rx or otherwise, on the day it happened or since. Some marketing has treated that review as if it were a green light. It was not one, and reputable telehealth programs should not describe it that way. If a company implies GHK-Cu, or any peptide like it, is now cleared because of that 2026 review, treat the claim as worth double-checking rather than taking it at face value. ## How to think about sources claiming to offer it right now Some sellers online do currently offer GHK-Cu, often as a research chemical rather than through a licensed telehealth intake. That distinction is significant. A research-labeled product is not intended for human use. It has not gone through the sourcing and quality controls a compounded prescription requires, and no licensed provider has reviewed it for you individually. If you come across a company claiming to sell GHK-Cu as a treatment through an online intake, it is reasonable to ask a few direct questions. Is the pharmacy actually licensed in your state? Does a real, individually licensed provider review your case, or is approval automatic? Is the company transparent about the current regulatory status, or does it gloss over it? A program that is straightforward about what it does not yet offer, the way this article is being straightforward about telos rx, tends to be more trustworthy than one that is vague. This is not a knock on the underlying research into GHK-Cu, which is a genuinely active area of study. It is a caution about the gap between compelling research and a compliant, individually reviewed clinical product, a gap that some sellers do not disclose clearly. Topical skincare products containing GHK-Cu occupy a different, more lightly regulated category than compounded or injectable forms, and they are not evaluated the same way a prescription would be. A cream sold as a cosmetic is not the same claim as a compounded peptide reviewed by a licensed provider for your specific case, even when the two share an ingredient name. ## Which is right for you today If GHK-Cu specifically is what brought you here, the honest answer is that telos rx cannot offer it today. No timeline for that changing is confirmed. If you are looking to start a compounded peptide protocol today, telos rx currently offers [BPC-157](https://www.telosrx.com/pages/bpc-157), [PT-141](https://www.telosrx.com/pages/pt-141), [NAD+ nasal spray](https://www.telosrx.com/pages/nad-nasal-spray), and [sermorelin](https://www.telosrx.com/pages/sermorelin). Each is reviewed and approved individually by a licensed provider. BPC-157 is the one most people researching tissue repair and recovery peptides tend to land on when GHK-Cu is not an option. It is studied in a similar general area and is available through telos rx today. It is a separate peptide with its own profile, not a substitute for GHK-Cu, and a provider can explain how the two differ if you are curious. [Start an intake](https://start.telosrx.com/start-online-visit/peptides) if you want to explore what is actually available right now. ## Frequently Asked Questions ### Does telos rx sell GHK-Cu? No. GHK-Cu is not currently part of the telos rx compounding program. It is under internal review, and there is no confirmed date for when, or whether, that will change. ### Why doesn't telos rx offer GHK-Cu yet? telos rx is reviewing GHK-Cu alongside several other research peptides for possible future inclusion in its program. That review has not concluded, and being under review is not the same as being approved or scheduled for launch. ### Did the 2026 PCAC review approve GHK-Cu for compounding? No. The Pharmacy Compounding Advisory Committee issued nonbinding recommendations in 2026 covering several research peptides. A recommendation to regulators is not a regulatory approval and did not change what any pharmacy is currently permitted to compound. ### Is GHK-Cu available anywhere legally right now? Some sellers offer it as a research chemical rather than as a reviewed clinical product, which is a different and less regulated category. A licensed telehealth program reviewing your case individually is not the same thing as buying an unreviewed research-labeled product online. ### What should I do if I am interested in GHK-Cu for skin or tissue support? You can read about its current status on the telos rx GHK-Cu page, and consider whether an available peptide such as BPC-157 fits your goals in the meantime. A provider can discuss how the available options compare to what you were originally researching. ### Will telos rx announce it if GHK-Cu becomes available? If GHK-Cu is added to the compounding program, the telos rx GHK-Cu page will reflect that change and an intake would become available at that point. Until then, no announcement means no change in availability. _telos rx is LegitScript-certified. Compounded medications broadly are not FDA-approved, and GHK-Cu is additionally not currently offered by telos rx. This article is general information, not medical advice, and does not replace guidance from your own provider._ Curious what telos rx does offer today? [See the current peptide lineup](https://www.telosrx.com/pages/bpc-157). --- > Source: [Telos RX](https://www.telosrx.com/blogs/glp1/ghk-cu-what-would-need-to-change-for-availability)